Using Magnetic Separation to Remove Contamination - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Using Magnetic Separation to Remove Contamination

Equipment and Processing Report

Untitled Document

Q. We have fine ferrous metal contamination in our pharmaceutical product, a free-flowing powder, even though we have a magnet. How can we remove the contamination?

A. Ferrous metal contamination can be reduced—if not virtually eliminated—with the use of magnetic separation equipment.  An understanding of the various types of magnetic separators, however, and their interaction with the physical nature of the product being purified is important. Temperature, flow rate, flow characteristics, and process issues are crucial factors for effective removal.

Magnetic materials lose strength when exposed to elevated temperatures, although some strength is recovered when the temperature returns to normal. Permanent magnets heated beyond certain temperatures may also suffer irreversible loss (i.e., a reduction in strength that cannot be recovered by cooling). It is important to note ambient and any clean-in-place (CIP) temperatures when choosing a magnet suitable for long-term separation performance. Rare earth (RE) magnetic separators, although more expensive, capture contaminants better at higher temperatures than conventional magnets. Standard RE magnets can work in temperatures up to 150 °F, while other RE models are designed to operate in temperatures up to 250 °F and even up to 400 °F.

Magnetic separators perform best when the contamination is presented to the surface of the separator. It is ideal to select a magnetic separator that provides for a thin burden depth over or under the magnet to ensure the magnet will have the most opportunity to capture the ferrous contamination. Plate, grate, and trap magnets have different characteristics for removing contaminants from different types of materials.

Many products exhibit different flow characteristics when damp or moist. Are there large chunks that may plug an opening or gap in the separator? Will the product flow freely through the selected magnetic separator? For example, a pharmaceutical powder with any significant moisture content will not flow between the tubes in a grate magnet assembly, even if they are positioned nearly one inch (25 mm) apart from each other.

The process design is also important. Issues include how the material is presented to the separator, whether the material is metered or has surge flow that needs to be handled, and where the magnetic separator is installed (e.g., prior to a filling/packaging machine, at the discharge end of a conveyor, beneath a hopper, or before the material drops into a bulk bag).  

A magnetic survey and appraisal of plant operations by an experienced professional can help to determine if your current magnetic installations are giving optimum protection, to learn what magnets can and cannot do, and to discover the advantages of newer technologies.

—Bill Dudenhoefer is manager of Separation Products at Eriez.

If you have a problem with your equipment or process, an industry expert may have the solution. Please send your question to Jennifer Markarian, editor of Equipment and Processing Report, and we may be able to provide an answer in a future issue. All questions will remain anonymous.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Equipment and Processing Report,
Click here